The HIV protease inhibitor, ritonavir, corrects diverse brain phenotypes across development in mouse model of DYT-TOR1A dystonia
Abstract
Ritonavir, identified by a DYT1 dystonia in vitro drug screen, corrects neuronal firing response and white matter deficits in the DYT1 mouse brain.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Aug 18, 2021
- Source ID
- 10.1126/scitranslmed.abd3904
Entities
People
- Bradley J Wilkes
- David Vaillancourt
- Jennifer T. Fox
- Joseph E. Rittiner
- Kanny K. Wan
- Matthew B. Boxer
- Matthew D. Hall
- Min Shen
- Miranda K. Shipman
- Nicole Calakos
- Ricardo Hernández
- Samarjit Patnaik
- Steven A. Titus
- Ya-qin Zhang
- Zachary F. Caffall
- Zhuyin Li
Organizations
- Duke University
- National Institutes of Health
- United States Department of Defense
- University of Florida